Tech Center 1600 • Art Units: 1648 1671
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17817382 | HPV VACCINE | Non-Final OA | Merck Sharp & Dohme LLC |
| 18560515 | Coronavirus Constructs and Vaccines | Non-Final OA | The Regents of the University of California |
| 17603789 | PHAGE TEST KIT | Non-Final OA | DSM IP Assets B.V. |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18021719 | RAPID AND LOW-COST NUCLEIC ACID DETECTION USING TRANSLATION-BASED SEQUENCE VERIFICATION ASSAYS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17310461 | CANCER SPECIFIC FRAMESHIFT VACCINES | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 18016932 | METHODS OF DIAGNOSTICS | Final Rejection | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18624656 | FREEZE DRIED VIRAL NANOPARTICLE CONSTRUCTS | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17634526 | NOVEL TREATMENT AND PREVENTION OF DISEASE BASED ON IMMUNOLOGICAL MEMORY | Final Rejection | Zeria Pharmaceutical Co., Ltd. |
| 18256844 | ASSAYS FOR RAPID DETECTION OF AIRBORNE VIRUSES INCLUDING INFLUENZA AND CORONAVIRUSES | Non-Final OA | TELEDYNE FLIR DEFENSE, INC. |
| 17845629 | Methods and Systems for Detection of Covid Variants | Non-Final OA | Laboratory Corporation of America Holdings |
| 18344952 | METHODS FOR DETERMINING SARS-COV-2 ANTIGEN AND ANTI-SARS-COV-2 ANTIBODY IN A SAMPLE | Non-Final OA | Abbott Laboratories |
| 18152432 | NON-REPLICATIVE TRANSDUCTION PARTICLES WITH ONE OR MORE NON-NATIVE TAIL FIBERS AND TRANSDUCTION PARTICLE-BASED REPORTER SYSTEMS | Non-Final OA | Roche Molecular Systems, Inc. |
| 18021348 | NOVEL CORONAVIRUS SARS-CoV-2 SAFE REPLICON SYSTEM AND USE THEREOF | Non-Final OA | SUN YAT-SEN UNIVERSITY |
| 17735780 | CHIMERIC IMMUNOGENS AND METHODS FOR MAKING POLYCLONAL ANTIBODIES AGAINST SPECIFIC EPITOPES | Non-Final OA | Agilent Technologies, Inc. |
| 18028245 | BACTERIAL PILUS PROTEIN COMPLEX FIMGT-DSF STABILIZED PROTEIN COMPLEXES FOR PRODUCING FILAMENTOUS PHAGES | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17512211 | DUAL-ENHANCED RAMAN SCATTERING-BASED BIOMOLECULAR SENSING SYSTEM USING GRAPHENE-PLASMONIC HYBRID NANOARRAY AND METHODS OF USE THEREOF | Final Rejection | Rutgers, The State University of New Jersey |
| 17800687 | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18503487 | Vaccines For Human Papilloma Virus And Methods For Using The Same | Final Rejection | Inovio Pharmaceuticals, Inc. |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18257889 | MULTIVALENT HVT VECTOR VACCINE | Final Rejection | INTERVET INC. |
| 18281416 | MICROORGANISM DISPLAYING ANTIGENIC PROTEIN OF THE SARS-CoV2 CORONAVIRUS | Non-Final OA | LES BIOTECHNOLOGIES ULYSSE INC. |
| 18032497 | COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES | Non-Final OA | Kshitij G. WAGH |
| 18275860 | Automatic Phagogram | Non-Final OA | INTELIPHAGE SRL |
| 17611063 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Final Rejection | Vir Biotechnology, Inc. |
| 17813157 | SPECIFIC HOST FACTOR OF HEPATITIS B VIRUS INFECTION, AND USE THEREOF | Non-Final OA | National Institute of Biological Sciences, Beijing |
| 17635537 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOLYTIC HERPES SIMPLEX VIRUS FOR SYSTEMIC ADMINISTRATION | Non-Final OA | IMMVIRA CO., LIMITED |
| 18248861 | METHOD AND COMPOSITON FOR TREATING CANCER USING A VACCINE | Non-Final OA | HPVVAX, LLC |
| 17909688 | SYSTEMS AND METHODS FOR GENERATING IMMUNE RESPONSES IN SUBJECTS USING MICROCHANNEL DELIVERY DEVICES | Final Rejection | AQUAVIT PHARMACEUTICALS, INC. |
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | Non-Final OA | Serimmune Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy